The Interfaith Alliance for Safer Communities Hosted A Roundtable Event - Covid-19: Faith as a Moral Framework for our Communities
7.9.2020 16:00:00 EEST | Business Wire | Press release
The Interfaith Alliance for Safer Communities (IAFSC), an NGO established to empower faith leaders to work for the safety and security of communities, has held a successful online interfaith roundtable event with representation from 50 participants representing 7 faiths from 18 countries.
Speaking about the event, Dr. Vinu Aram (Director of Shanti Ashram and Co-Moderator of Religions for Peace) said, “I want to thank the Interfaith Alliance for Safer Communities for this meeting today. The work of the Interfaith Alliance is so important: in the disruption of the ways we worked together as communities during Covid-19, we have found that children have become more vulnerable... While every nation is trying to find its own solution, those of us who work with children have to be greater advocates for their cause.”
Chief Executive of the IAFSC, Dana Humaid, said “Faith has rarely been more important or powerful than in the current crisis. The IAFSC hosted this event in order to allow discussion and facilitate knowledge-sharing from different religions and communities on a global scale. Faith leaders have the power to assist their communities, to be advocates for those in need, to make a difference and offer comfort and also to try and reduce the suffering of people under their watch.”
The ongoing Covid-19 pandemic has been unprecedented in modern times, and has had a significant impact on the physical, mental and spiritual wellbeing of our communities. Millions have lost their jobs and are facing struggles such as hunger and homelessness. This pandemic has had unforeseen consequences as well, such as a surge in the cases of child sexual abuse as well as an increase in hate crimes based on race and religion.
Key Outcomes
The roundtable discussions aimed to address the most significant problems being faced by our communities today.
Supporting those most impacted by coronavirus in rebuilding their lives
- We are all impacted by this pandemic, we are not all affected the same way.
- The role of faith and faith leaders is to build, promote and invigorate a spirit of resilience.
- When faith leaders aren’t able to contact their community and provide them with help or assistance in a difficult time, it is a challenge for everyone in the community.
- Faith leaders have been taking on the bulk of the work in some communities.
- We need to be careful of our blind spots, we cannot create a situation in which we overlook other communities that now need our help, such as those that may not be considered traditionally vulnerable sectors of society.
Protecting the digital dignity of children and supporting the victims and their families
- Faith leaders can be champions in leading the prevention of sexual exploitation.
- It is important to base our responses on data and evidence and go from there.
- No one is an expert in the prevention of exploitation. Community is key.
- We need to increase budgets for social and health services.
- Family and family stability are also vital.
- Education, mobilization, support and universal healthcare are all necessary in improving our communities.
Among others, organisations represented included: Arigatou International, ECPAT International, New York Board of Rabbis, Conference of European Rabbis, Bahá'í International Community, Peres Center for Peace and Innovation, Shanti Ashram, World Economic Forum, UNICEF, Conference of European Churches, Markaz Knowledge City (India), and Online Anti-Semitism Task Force.
Visit https://iafsc.org/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200907005253/en/
Contact information
For more information:
Caroline Sullivan
media@iasfc.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN ® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 09:00:00 EEST | Press release
Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month 6 as the primary endpoint. Secondary endpoints include changes in monthly headache days, acute medication days and migraine frequency during two-week periods at the end of each injection cycle. “Achieving patient recruitment for both MINT-C and MINT-E six months ahead of plan is an important milestone for our XEOMIN® migraine preven
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 08:10:00 EEST | Press release
Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Malaysia 2026–2027 (VM2026–2027), this partnership merges Tourism Malaysia’s destination marketing with Alipay+’s global wallet ecosystem and AI capabilities. It aims to create a highly intelligent digital journey, connecti
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe atopic dermatitis, sustained through Week 52.1 The results will be presented at The Pediatric Dermatology Research Alliance (PeDRA) Annual Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014705800/en/ Up to 25% of children are affected by atopic dermatitis - the most common inflammatory skin disorder in this population - and around one-third of these children have moderate-to-severe disease.11,12 Atopic dermatitis creates a high burden for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school, and social confidence.2-8 Despite the high prevalence and significant burden, treatment options are
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 03:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re excited at the potential to fundamentally change how NT1 is managed across Japan and China,” said Giles Platford, president, International, Takeda. “We’ve heard from patients how ORZEYFUL has improved their daily functioning and quality of life, enormously meaningful outcomes for a condition known to impact many aspects of a person’s life, including work, education and social interactions.”1,2,3,4,5 NT1 is a chronic, rare neurological disease driven by orexin deficiency. People experience a range of symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disr
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 03:10:00 EEST | Press release
Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to expand treatment options for patients with IBD.2,3 On October 18, Celltrion will host a symposium titled "Navigating the Treatment Journey with Subcutaneous Infliximab Across Clinical Scenarios," Chaired by Professor Peter M. Irving of King's College London, UK, a leading IBD expert. Celltrion will also host two MTE sessions at its booth. In the firs
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
